Please login to the form below

Not currently logged in
Email:
Password:

Tobira Therapeutics

This page shows the latest Tobira Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Allergan buys regenerative medicine firm LifeCell for $2.9bn

Allergan buys regenerative medicine firm LifeCell for $2.9bn

Allergan's other deals in 2016 have included a $1.7bn acquisition of Tobira Therapeutics - which gave it two drug candidates for non-alcoholic steatohepatitis (NASH) - a $639m takeover of dermatology

Latest news

  • Gilead chalks up trial success for new NASH drug Gilead chalks up trial success for new NASH drug

    Along with selonsertib, Gilead is also developing an FXR agonist called GS-9674 in phase I trials and acquired a wholly-owned subsidiary of Nimbus Therapeutics for $1.2bn earlier this ... Allergan has been building a pipeline of candidates through a

  • Allergan buys two NASH drug developers in one day Allergan buys two NASH drug developers in one day

    Allergan buys two NASH drug developers in one day. More than $1.7bn paid for Tobira Therapeutics and Akarna Therapeutics. ... Allergan has gone on the acquisition trail once again, stumping up more than $1.7bn for non-alcoholic steatohepatitis (NASH)

  • A competitive edge

    TBR 652 is currently being developed by Tobira Therapeutics. A phase IIa proof-of-concept trial evaluated the antiviral activity, safety and pharmacokinetics of TBR 652 in treatment-experienced, CCR5-naïve ... Ampyra (Acorda Therapeutics). Multiple

More from news
Approximately 3 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    Hogging the headlines …. Featuring in two entries in the September Deal Watch table, Allergan was busy splashing the cash with a $1.7bn acquisition of Tobira Therapeutics, hotly followed by the ... 1, 710. Tobira Therapeutics / Allergan. Acquisition

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics